Telix Pharmaceuticals (TLX) investor relations material

Opening remarks and agenda

• AGM opened with confirmation of quorum, acknowledgment of traditional custodians, and addresses from the Interim Chairman and CEO outlining the agenda and formal business items including voting and Q&A sessions.

• Meeting agenda included performance review, board introductions, and strategic priorities for 2026.

• Housekeeping and procedural instructions provided for both in-person and online attendees.

Financial performance review

• Achieved $804 million in revenue for 2025, a 56% year-on-year increase, driven by Illuccix and Gozellix sales.

• First quarter 2026 revenue reached $230 million, up 4% from the prior year, with Q1 revenue increasing by 11% and volumes by 5% quarter-on-quarter.

• FY 2026 revenue guidance set at $950M–$970M.

• Illuccix and Gozellix expanded globally, now available in 22 countries, with over 2.9 million commercial and clinical doses delivered globally in 2025.

• Refinanced $600 million convertible bonds, enhancing financial flexibility.

Board and executive committee updates

• Three new U.S.-based directors appointed: David Gill, William Jellison, and Dr. Maria Rivas, strengthening expertise in healthcare, finance, and U.S. capital markets.

• Board renewal supports global expansion and dual ASX/Nasdaq listing.

• Board includes Interim Chair Mark Nelson, CEO Christian Behrenbruch, and several non-executive directors.

• David Gill to assume Chair role in the near future.